Effetto degli SGLT2-i sull’ematocrito: “Trick or Treat”?

SGLT2 inhibitors (SGLT2i) are widely used for type 2 diabetes (T2D) due to their cardiovascular and renal benefits. This case series aims to highlight the diagnostic and therapeutic challenges related to SGLT2i-induced erythrocytosis. We retrospectively analyzed 53 T2D patients with this condition. Most cases were benign and self-limiting, with Hb/Hct normalization after drug discontinuation. No thrombotic events were observed. Clinical monitoring is warranted to avoid unnecessary discontinuations and optimize management.